Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion

This study is testing a combination of proton beam radiation therapy followed by two immunotherapy/anti-angiogenesis drugs (atezolizumab and bevacizumab, sold as Tecentriq and Avastin) for primary liver cancer (hepatocellular carcinoma) that has grown into the portal vein — one of the main vessels supplying the liver. **You may be eligible if...** - You are 20 or older with confirmed liver cancer (hepatocellular carcinoma) - Your cancer has grown into the portal vein (a specific blood vessel in the liver, graded Vp2–4) - You have at least one measurable liver tumor - Your liver function is reasonably preserved (Child-Pugh class A) - Your performance status is good (ECOG 0–1) - Your blood counts, liver, and kidney tests meet minimum thresholds **You may NOT be eligible if...** - Your liver function is significantly impaired (Child-Pugh B or C) - You have active, uncontrolled hepatitis B or C - You have active autoimmune disease or a history of organ transplantation - You have serious heart problems or uncontrolled bleeding risk - You are pregnant or planning to become pregnant Talk to your doctor to see if this trial is right for you.